Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Altimmune's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Altimmune's regulatory disclosures and financial reporting.
State Street Corporation reports shared beneficial ownership of 5.5% of Altimmune Inc. common stock. The filing states 7,145,550 shares as the number of shares for which State Street has shared dispositive power, with 7,012,433 shares of shared voting power, as of 03/31/2026. The schedule identifies affiliated investment-advisory subsidiaries and is signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, on 05/12/2026.
Altimmune, Inc. ownership filing: an investment group led by Viking Global reports beneficial ownership of 13,400,000 shares of Altimmune common stock, representing 6.7% of the class based on 194,199,358 shares outstanding as of April 24, 2026. The holdings reflect 4,690,000 shares owned by Viking Global Opportunities (VGOP) and 2,010,000 shares owned by Viking Global Opportunities Vintage IV (VGOVIV), plus corresponding 6,700,000 warrants exercisable at $3.00 per share that give the reporting group the right to purchase additional shares. Ownership is reported across multiple related entities and two named individuals as shared voting and dispositive power.
Altimmune reports Schedule 13G ownership by TCG Crossover funds and Chen Yu. The filing lists aggregate shared voting and dispositive power of 10,000,000 shares for each TCG Crossover fund entity (reported as 5.0% of the class) and reports 20,000,000 shares attributable to Chen Yu (reported as 9.8% of the class). The filing states 194,199,358 shares outstanding as of April 24, 2026 following an underwritten offering and references an additional 10,000,000 shares issuable upon exercise of Common Warrants held by the TCG Crossover entities.
Altimmune, Inc. director Teri L. Lawver received a grant of stock options as part of non-employee director compensation. The award covers 48,800 stock options with an exercise price of $2.82 per share and expires on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service. After this grant, the filing shows 48,800 derivative securities held.
Altimmune, Inc. director Catherine A. Sohn received a grant of stock options as part of her non-employee director compensation. She was awarded 48,800 stock options to buy common stock at an exercise price of $2.82 per share, with no cash paid at grant.
The options become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to her continued service. Any unexercised options expire on May 1, 2036, and her reported post-transaction holdings in this option grant are 48,800 options.
Altimmune, Inc. director Diane Jorkasky received a grant of stock options covering 48,800 shares of common stock as board compensation. The options carry an exercise price of $2.82 per share and expire on May 1, 2036. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, conditioned on her continued service as a non-employee director.
Altimmune, Inc. director Klaus Schafer received a grant of stock options as part of non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued board service. After this grant, he holds 48,800 options directly.
Altimmune, Inc. director Wayne Pisano received a grant of stock options to acquire 48,800 shares of common stock at an exercise price of $2.82 per share. The options were issued as part of the company’s non-employee director compensation policy.
The options expire on May 1, 2036 and cover 48,800 underlying shares of common stock. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on Mr. Pisano’s continued service.
Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The 48,800 underlying shares become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, as long as Hodges continues to serve the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Altimmune, Inc. reporting persons RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah disclose beneficial ownership of 13,000,000 shares of common stock (shared voting and dispositive power). The filing states this equals 6.5% of the class, calculated using 130,105,177 shares outstanding as of March 13, 2026 and 64,250,000 shares issued in the public offering that closed on April 24, 2026. The Fund directly holds 6,500,000 shares and Common Warrants exercisable for up to 6,500,000 shares; RA Capital and the named individuals describe delegated voting/dispositive arrangements and disclaim certain beneficial‑ownership statuses for specific regulatory purposes.